相关实验视频
Updated: Jan 13, 2026

08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
41.2K
梅波利祖马布在儿科重症酸性喘中的实际有效性和安全性:一项多中心研究
Nadira Nabiyeva Çevik1, Melike Ocak1, Gaye Kocatepe2
1Department of Pediatric Allergy, Hacettepe University, Faculty of Medicine, Ankara, Türkiye.
Pediatric pulmonology
|January 12, 2026
概括
梅波利祖马布在24个月的时间里显著降低了患有严重埃索因性喘的儿童的恶化和口服皮质类固醇的使用,改善了肺功能和喘控制.
科学领域:
- 儿科肺病学 儿科肺病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿童严重喘 (SA) 在发病率和医疗保健利用方面存在重大挑战.
- 梅波利祖马布 (Mepolizumab) 是一种抗素-5生物药物,适用于6岁及以上儿童的严重酸性喘 (SEA).
- 有限的长期真实世界数据存在于mepolizumab在儿科SEA的使用.
研究的目的:
- 评估梅波利祖马布在儿科SEA的长期安全性和有效性.
- 评估对肺功能的影响,口服皮质类固醇 (OCS) 的减少,以及恶化的频率.
- 分析喘控制的变化和埃索诺菲尔细胞的数量.
主要方法:
- 对33名儿科SEA患者 (6-17岁) 进行了回顾性多中心研究,这些患者接受了mepolizumab治疗.
- 纳入标准:GINA定义的SA,频繁的恶化,OCS使用,高剂量的ICS和升高的乙氨基酸.
- 在24个月内收集的数据包括恶化,肺功能测试 (PFT),OCS使用,喘控制测试 (ACT) 成绩和不良事件.
主要成果:
- 梅波利祖马布治疗导致恶化率显著降低 (中位数为7至0-0.05/年) 和OCS使用 (87.9%在3个月内没有OCS).
- 控制喘 (ACT分数) 和肺功能 (FEV1%) 显示显著改善 (p < 0.001).
- 乙氨基酸细胞数量大幅下降 (中位数为460至50个细胞/μL,p < 0.001),报告了良好的耐受性.
结论:
- 梅波利祖马布在24个月的时间内在儿科SEA患者中表现出持续的有效性和良好的安全性.
- 生物药物显著改善了喘控制,肺功能,并减少了恶化和OCS依赖.
- 这些发现支持mepolizumab在治疗儿科SEA中的实际实用性,强调了患者选择和监测的重要性.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Antiasthma Drugs: Methylxanthines
1.6K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.6K
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K

